SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009324
Filing Date
2022-05-11
Accepted
2022-05-11 16:09:45
Documents
72
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20220331.htm   iXBRL 10-Q 1642219
2 EX-10.2 glue-ex10_2.htm EX-10.2 77458
3 EX-31.1 glue-ex31_1.htm EX-31.1 24067
4 EX-31.2 glue-ex31_2.htm EX-31.2 24047
5 EX-32.1 glue-ex32_1.htm EX-32.1 22495
  Complete submission text file 0000950170-22-009324.txt   6488708

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20220331_pre.xml EX-101.PRE 322714
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT glue-20220331_def.xml EX-101.DEF 160407
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT glue-20220331_cal.xml EX-101.CAL 38585
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20220331.xsd EX-101.SCH 47183
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20220331_lab.xml EX-101.LAB 414706
66 EXTRACTED XBRL INSTANCE DOCUMENT glue-20220331_htm.xml XML 1030001
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 22913792
SIC: 2836 Biological Products, (No Diagnostic Substances)